Thieler Law Corp, member of the Investor Attorney Network, is investigating whether members of the board of directors of Receptos Inc (NASDAQ: RCPT) acted responsibly on behalf of investors’ profitability in the planned $7.3 billion sale to Celgene Corporation (NASDAQ: CELG).

On July 14, 2015, Receptos Inc (NASDAQ: RCPT) and Celgene Corporation (NASDAQ: CELG)announced that they had entered into a merger agreement. Under the terms of the merger agreement, Celgene will offer Receptos shareholders $ 232.00 per share in cash for all outstanding shares.    

Based in San Diego, CA, and founded in 2008 Receptos Inc  is a clinical-stage biopharmaceutical company that is focused on the discovery, development, and commercialization of therapeutics in immune disorders. The company was formerly known as Receptor Pharmaceuticals Inc and changed its name to Receptos Inc in May 2009.

The investigation is looking to uncover whether Receptos Inc was undervalued at the cost of the shareholders considering one analyst’s opinion of their stock is valued at $348.00 per share.

If you purchased Receptos Inc (NASDAQ: RCPT) prior to July 14, 2015, you should contact Thieler Law Corp at mail@thielerlaw.com or call +1 (619) 377 - 4324.

Thieler Law Corp

2534 State Street - Suite 406,

San Diego, CA 92101

by

email: mail@thielerlaw.com 

or

telephone at +1 (619) 377 - 4324

or

visit our website http://www.thielerlaw.com/ 

or

Facsimile: +1 (619) 785 – 3185